Stromal PD-L1 Expression Is Associated With Better Disease-Free Survival in Triple-Negative Breast Cancer

Programmed death ligand 1 expression in triple-negative breast cancer is associated with tumour-infiltrating lymphocytes and improved outcome

(2016) Rhiannon K Beckers et al.   HISTOPATHOLOGY

GATA-3 and FOXA1 expression is useful to differentiate breast carcinoma from other carcinomas

(2016) Drew G. Davis et al.   HUMAN PATHOLOGY

Prognostic significance of PD-L1 and PD-L2 in breast cancer

(2016) Mauricio Z. Baptista et al.   HUMAN PATHOLOGY

The Presence of Extensive Retraction Clefts in Invasive Breast Carcinomas Correlates With Lymphatic Invasion and Nodal Metastasis and Predicts Poor Outcome

(2015) Geza Acs et al.   AMERICAN JOURNAL OF SURGICAL PATHOLOGY

PD-L1 protein expression in breast cancer is rare, enriched in basal-like tumours and associated with infiltrating lymphocytes

(2015) H. R. Ali et al.   ANNALS OF ONCOLOGY

Clinical validity of tumor-infiltrating lymphocytes analysis in patients with triple-negative breast cancer

(2015) G. Pruneri et al.   ANNALS OF ONCOLOGY

High Pathologic Complete Response in Her2-Positive, Early-Stage Breast Cancer to a Novel Nonanthracycline Neoadjuvant Chemotherapy

(2015) Amelia B. Zelnak et al.   Clinical Breast Cancer

The prognostic value of PD-L1 expression for non-small cell lung cancer patients: A meta-analysis

(2015) A. Wang et al.   EJSO

Combination cancer immunotherapy and new immunomodulatory targets

(2015) Kathleen M. Mahoney et al.   NATURE REVIEWS DRUG DISCOVERY

PDL1 expression in inflammatory breast cancer is frequent and predicts for the pathological response to chemotherapy

(2015) François Bertucci et al.   Oncotarget

Prognostic and predictive value of PDL1 expression in breast cancer

(2015) Renaud Sabatier et al.   Oncotarget

PD-L1 marks a subset of melanomas with a shorter overall survival and distinct genetic and morphological characteristics

(2014) D. Massi et al.   ANNALS OF ONCOLOGY

Programmed Cell Death 1 (PD-1) and Its Ligand (PD-L1) in Common Cancers and Their Correlation with Molecular Cancer Type

(2014) Z. Gatalica et al.   CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION

Programmed death ligand 1 expression and tumor-infiltrating lymphocytes in glioblastoma

(2014) Anna Sophie Berghoff et al.   NEURO-ONCOLOGY

PD-L1 expression in melanoma shows marked heterogeneity within and between patients: implications for anti-PD-1/PD-L1 clinical trials

(2014) Jason Madore et al.   Pigment Cell & Melanoma Research

PD-L1 Expression in Triple-Negative Breast Cancer

(2014) E. A. Mittendorf et al.   Cancer Immunology Research

Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies

(2011) Brian D. Lehmann et al.   JOURNAL OF CLINICAL INVESTIGATION

Breast Cancer Subtypes and the Risk of Local and Regional Relapse

(2010) K. David Voduc et al.   JOURNAL OF CLINICAL ONCOLOGY

Prediction of Local Recurrence, Distant Metastases, and Death After Breast-Conserving Therapy in Early-Stage Invasive Breast Cancer Using a Five-Biomarker Panel

(2009) Ewan K.A. Millar et al.   JOURNAL OF CLINICAL ONCOLOGY

Residual breast cancers after conventional therapy display mesenchymal as well as tumor-initiating features

(2009) C. J. Creighton et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Intrinsic Resistance of Tumorigenic Breast Cancer Cells to Chemotherapy

(2008) X. Li et al.   JNCI-Journal of the National Cancer Institute